Clindamycinum [Inn-Latin] en es it fr

Clindamycinum [Inn-Latin] Brand names, Clindamycinum [Inn-Latin] Analogs

Clindamycinum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Clindamycinum [Inn-Latin] Chemical_Formula


Clindamycinum [Inn-Latin] RX_link

Clindamycinum [Inn-Latin] fda sheet

Clindamycinum_[Inn-Latin] FDA

Clindamycinum [Inn-Latin] msds (material safety sheet)

Clindamycinum [Inn-Latin] Synthesis Reference

Birkenmeyer, U.S. Pat. 3,475,407(1970)

Clindamycinum [Inn-Latin] Molecular Weight

424.984 g/mol

Clindamycinum [Inn-Latin] Melting Point

255 oC

Clindamycinum [Inn-Latin] H2O Solubility

30.6 mg/L

Clindamycinum [Inn-Latin] State


Clindamycinum [Inn-Latin] LogP


Clindamycinum [Inn-Latin] Dosage Forms

Capsules; Intramuscular solution; Intravenousparenteral solution; Topical solution; Topical lotion; Topical gel; Vaginal cream; Vaginal ovules

Clindamycinum [Inn-Latin] Indication

For the treatment of serious infections caused by susceptible anaerobic bacteria (anaerobes, streptococci, pneumococci, and staphylococci)

Clindamycinum [Inn-Latin] Pharmacology

Clindamycin is an antibiotic, similar to and a derivative of lincomycin. Clindamycin can be used in topical or systemic treatment. It is effective as an anti-anaerobic antibiotic and antiprotozoal.

Clindamycinum [Inn-Latin] Absorption

- 90% - oral

Clindamycinum [Inn-Latin] side effects and Toxicity

Orally and parenterally administered clindamycin has been associated with severe colitis (pseudomembranous colitis) which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.

Clindamycinum [Inn-Latin] Patient Information

Clindamycinum [Inn-Latin] Organisms Affected

Enteric bacteria and other eubacteria